OBJECTIVE: To evaluate the effect of episodic antiretroviral therapy on quality of life (QOL). DESIGN: This was a substudy of the Strategies of Management of Antiretroviral Therapy study, in which patients were randomized to continuous versus CD4 cell count-guided episodic antiretroviral therapy. QOL assessments included an analog scale for current health and the Short-Form 12 Item Survey, a standard abbreviated QOL instrument. RESULTS: A total of 1225 patients had QOL assessments over a mean follow-up time of 2.4 years. Most (76%) were on antiretroviral therapy at enrollment; the median CD4 lymphocyte count was 575 (interquartile range: 455 to 784) cells/mm3; and mean current health was 75 on a scale from 0 to 100, and 50% reported very good or excellent general health. Through follow-up, whenever QOL outcomes differed, the results were inferior among patients in the episodic therapy group compared with the continuous therapy group (current health, Physical Health Component Score [both P = 0.05], general health perceptions, physical functioning, and energy [all P = 0.03]). HIV disease progression (opportunistic disease or death) was more common in the episodic therapy arm and was preceded by marked declines in QOL, but excluding participants with disease progression had minimal effect on QOL comparisons. CONCLUSION: CD4 count-guided episodic use of antiretroviral therapy resulted in inferior QOL compared with continuous therapy.
RCT Entities:
OBJECTIVE: To evaluate the effect of episodic antiretroviral therapy on quality of life (QOL). DESIGN: This was a substudy of the Strategies of Management of Antiretroviral Therapy study, in which patients were randomized to continuous versus CD4 cell count-guided episodic antiretroviral therapy. QOL assessments included an analog scale for current health and the Short-Form 12 Item Survey, a standard abbreviated QOL instrument. RESULTS: A total of 1225 patients had QOL assessments over a mean follow-up time of 2.4 years. Most (76%) were on antiretroviral therapy at enrollment; the median CD4 lymphocyte count was 575 (interquartile range: 455 to 784) cells/mm3; and mean current health was 75 on a scale from 0 to 100, and 50% reported very good or excellent general health. Through follow-up, whenever QOL outcomes differed, the results were inferior among patients in the episodic therapy group compared with the continuous therapy group (current health, Physical Health Component Score [both P = 0.05], general health perceptions, physical functioning, and energy [all P = 0.03]). HIV disease progression (opportunistic disease or death) was more common in the episodic therapy arm and was preceded by marked declines in QOL, but excluding participants with disease progression had minimal effect on QOL comparisons. CONCLUSION:CD4 count-guided episodic use of antiretroviral therapy resulted in inferior QOL compared with continuous therapy.
Authors: Leonard Emuren; Seth Welles; Grace Macalino; Alison A Evans; Marcia Polansky; Anuradha Ganesan; Rhonda E Colombo; Brian K Agan Journal: Qual Life Res Date: 2020-02-20 Impact factor: 4.147
Authors: Alan R Lifson; Birgit Grund; Edward M Gardner; Richard Kaplan; Eileen Denning; Nicole Engen; Catherine L Carey; Fabian Chen; Sounkalo Dao; Eric Florence; Jesus Sanz; Sean Emery Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Daniel J Skiest; Amy Krambrink; Zhaohui Su; Kevin R Robertson; David M Margolis Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731